Suppr超能文献

前列腺素E1输注对雷诺综合征的血液流变学影响。

Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.

作者信息

Lucas G S, Simms M H, Caldwell N M, Alexander S J, Stuart J

出版信息

J Clin Pathol. 1984 Aug;37(8):870-3. doi: 10.1136/jcp.37.8.870.

Abstract

Eighteen patients with severe Raynaud's syndrome had impaired deformability of erythrocytes, as measured by filtration through 5 micron diameter pores, compared with 19 healthy controls. The patients were given prostaglandin E1 (PGE1) or placebo by intravenous infusion for 72 h to assess the haemorrheological action of PGE1. Contrary to a previous report, PGE1 did not improve erythrocyte filterability. Infusion of PGE1 did, however, evoke an acute phase response with hyperproteinaemia and a leucocytosis and is a potentially important mediator of this stress response in patients with vascular disease.

摘要

与19名健康对照者相比,18名重度雷诺综合征患者的红细胞变形能力受损,这是通过红细胞经直径5微米的小孔滤过进行测量的。这些患者通过静脉输注给予前列腺素E1(PGE1)或安慰剂,持续72小时,以评估PGE1的血液流变学作用。与之前的一份报告相反,PGE1并未改善红细胞滤过率。然而,输注PGE1确实引发了急性期反应,伴有高蛋白血症和白细胞增多,并且是血管疾病患者这种应激反应的潜在重要介质。

相似文献

1
Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.
J Clin Pathol. 1984 Aug;37(8):870-3. doi: 10.1136/jcp.37.8.870.
2
A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
Ann Rheum Dis. 1985 Nov;44(11):754-60. doi: 10.1136/ard.44.11.754.
3
Assessment of platelet function in patients with Raynaud's syndrome.
J Clin Pathol. 1984 Feb;37(2):182-7. doi: 10.1136/jcp.37.2.182.
4
5
Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.
Br Med J (Clin Res Ed). 1981 Dec 12;283(6306):1608-9. doi: 10.1136/bmj.283.6306.1608-e.
7
Prostaglandin E1 vasospastic disease and thermography.
Ann Rheum Dis. 1985 Feb;44(2):73-8. doi: 10.1136/ard.44.2.73.
8
Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
Ann Rheum Dis. 1981 Aug;40(4):350-4. doi: 10.1136/ard.40.4.350.
10
Treatment of severe Raynaud's phenomenon with prostaglandin E1.
Ir J Med Sci. 1981 Jun;150(6):190-1. doi: 10.1007/BF02938232.

引用本文的文献

1
Nisoldipine in primary Raynaud's phenomenon.
Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.
2
Clinical and rheological effects of nifedipine in Raynaud's phenomenon.
Br J Clin Pharmacol. 1986 Oct;22(4):449-54. doi: 10.1111/j.1365-2125.1986.tb02916.x.
3
The clinical importance of erythrocyte deformability, a hemorrheological parameter.
Ann Hematol. 1992 Mar;64(3):113-22. doi: 10.1007/BF01697397.

本文引用的文献

1
BLOOD VISCOSITY AND RAYNAUD'S DISEASE.
Lancet. 1965 May 22;1(7395):1086-8. doi: 10.1016/s0140-6736(65)92673-5.
2
Treatment of vasospastic disease with prostaglandin E1.
Br Med J. 1980 Oct 18;281(6247):1031-4. doi: 10.1136/bmj.281.6247.1031.
3
Haematological stress syndrome in atherosclerosis.
J Clin Pathol. 1981 May;34(5):464-7. doi: 10.1136/jcp.34.5.464.
4
Serial study of C-reactive protein during infection in leukaemia.
J Clin Pathol. 1981 Mar;34(3):263-6. doi: 10.1136/jcp.34.3.263.
5
Characterization of a leukocyte-derived endogenous mediator responsible for increased plasma fibrinogen.
Ann N Y Acad Sci. 1982;389:338-53. doi: 10.1111/j.1749-6632.1982.tb22148.x.
6
Leukocytic pyrogen: a major mediator of the acute phase reaction.
Ann N Y Acad Sci. 1982;389:323-37. doi: 10.1111/j.1749-6632.1982.tb22147.x.
8
Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome.
Br J Haematol. 1980 Aug;45(4):651-8. doi: 10.1111/j.1365-2141.1980.tb07188.x.
9
Erythrocyte filtrability measurement by the initial flow rate method.
Biorheology. 1983;20(2):199-211. doi: 10.3233/bir-1983-20209.
10
Immunoregulatory activity of metabolites of arachidonic acid and their role in inflammation.
Br Med Bull. 1983 Jul;39(3):243-8. doi: 10.1093/oxfordjournals.bmb.a071827.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验